What Is the IBB ETF? A Complete Guide to Returns, Expense Ratio, Holdings, and Alternative ETFs
The iShares Biotechnology ETF (IBB) tracks the NYSE Biotechnology Index and offers diversified exposure to companies developing therapeutics and new drugs. Its expense ratio, dividends, and differences from similar biotech ETFs such as XBI are the key selection criteria, and they are closely tied to the sector outlook.
SubscribeWhat Is the iShares Biotechnology ETF?
This is a sector ETF that tracks an index of biotechnology companies listed in the United States. It holds therapeutics developers and biotech process-related companies broadly on a market-capitalization basis, allowing investors to follow the performance of the entire biotech sector through a single ticker.
It suits investors who find the volatility of individual drug developers burdensome but still want diversified exposure to biotech sector growth.
It is a passively managed (index-tracking) ETF run by iShares.
How Does the iShares Biotechnology ETF Invest?
| Item | Details |
|---|---|
| Tracked Index | NYSE Biotechnology Index |
| Management Style | Passive (index-tracking) |
| Rebalancing Frequency | Quarterly (full reconstitution once a year) |
| Dividend Frequency | Quarterly |
| Expense Ratio | 0.44% |
| Issuer | iShares |
The fund holds US-listed biotech companies using a modified market-cap weighting method, and it places caps on the weights of top holdings to ease concentration in specific stocks. The index is rebalanced every quarter and fully reconstituted once a year to reflect changes in sector composition.
- Broad diversification concentrated in the biotech sector
- Weight caps on top holdings to ease concentration
iShares Biotechnology ETF Size and Costs (AUM and Expense Ratio)
Assets under management (AUM) stand at $10.9B, and the expense ratio is 0.44% per year.
Compared with XBI, which shares the same biotech theme, it differs in holding structure and weighting method, so the share of large-cap stocks and the nature of its volatility are different.
iShares Biotechnology ETF Performance and Trends
1-Year Price Performance
Dividend & Yield
52-Week Price RangeThe biotech sector reacts sensitively to clinical trial results, regulatory approvals, and the interest rate environment, so volatility tends to be high. The sector as a whole tends to move up and down repeatedly depending on growth expectations and the interest rate cycle.
In the biotech sector, fund flows fluctuate noticeably depending on the market's risk appetite. Inflows tend to rise when innovation and new drug momentum come into focus, while outflow pressure tends to grow during risk-averse phases.
iShares Biotechnology ETF Pros and Cons
Its strengths are biotech sector diversification and a weight-cap structure, while its weakness is the high volatility of the sector itself.
💪 Key Strengths
⚠️ Points to Watch
iShares Biotechnology ETF Alternative ETFs and Related Products
A direct substitute within the same biotech theme is XBI, which has a structure closer to equal weighting and therefore larger exposure to small and mid-cap biotech. To gain exposure to the broader healthcare sector, you can consider XLV and VHT together, and for a focus on genomics and next-generation biotech innovation, ARKG is also a candidate for comparison. Meanwhile, HACK, POWR, and AIPO, which appear in the table as well, belong to cybersecurity and power infrastructure themes and are in a different sector from biotech, so consider the difference in theme first rather than simply comparing expense ratios or strategies.
Peer Comparison ETFs| Ticker | Name | Price | Change | AUM | Total Expense Ratio | Dividend Yield | 1Y |
|---|---|---|---|---|---|---|---|
 HACK | Amplify Cybersecurity ETF | $133.52 | +1.6% | $3.7B | 0.60% | 0.04% | +50.7% |
 AIPO | Defiance AI & Power Infrastructure ETF | $25.36 | +3.5% | $819.4M | 0.69% | 0.01% | +2.5% |
 POWR | iShares U.S. Power Infrastructure ETF | $25.08 | +1.8% | $437.9M | 0.39% | 2.09% | +2.4% |
 ELFY | ALPS Electrification Infrastructure ETF | $38.02 | +2.1% | $163.9M | 0.50% | 1.16% | +2.3% |
Top Holdings| Ticker | Name | Weight | Price | Change | Market Cap | P/E | Dividend Yield |
|---|---|---|---|---|---|---|---|
| VRTX | Vertex Pharmaceuticals Inc | 0.16% | $521.03 | +0.7% | $132.1B | 30.3 | - |
| AMGN | AMGEN Inc | 0.15% | $447.95 | +0.8% | $242.2B | 27.8 | 2.26% |
| GILD | Gilead Sciences Inc | 0.15% | $159.08 | +0.3% | $197.3B | - | 2.07% |
| REGN | Regeneron Pharmaceuticals Inc | 0.12% | $816.10 | +1.0% | $84.0B | 20.2 | 0.43% |
| ALNY | Alnylam Pharmaceuticals Inc | 0.04% | $226.79 | -0.4% | $30.3B | 38.3 | - |
| ARGX | Argen X SE ADR | 0.04% | $882.48 | +1.5% | $55.5B | 33.6 | - |
iShares Biotechnology ETF Investor Checkpoints
These are points to review before investing in IBB. Biotech sector ETFs carry both growth potential and volatility, so it is wise to check costs, concentration, and currency exposure in advance.
| Checkpoint | What to Check | Current Status |
|---|---|---|
| 💵 Expense Ratio | Check the cumulative impact over a long holding period | Annual fee applies |
| 📊 Sector Concentration | Degree of exposure to the single biotech sector | High concentration |
| 🌪 Volatility | Sensitivity to clinical and regulatory events | Needs checking |
| 💱 Exchange Rate | Impact on returns converted to Korean won | No currency hedge |
Events such as clinical failures and regulatory changes are the main factors that amplify short-term volatility across the sector. Because of its single-sector concentration, drawdowns can be larger than those of broad core ETFs during market corrections.
It is a representative sector ETF suited to investors seeking diversified exposure to the biotechnology sector. To increase exposure to small and mid-cap biotech, XBI is an alternative, and for broader healthcare, ETFs such as XLV and VHT are also options.
SubscribeDisclaimer: This content is for informational purposes only and does not constitute investment advice. All investment responsibility lies with the investor.
This article reflects information as of June 21, 2026.
Today's 5 AI picks, all free